Interaction of the human prostacyclin receptor and the NHERF4 family member intestinal and kidney enriched PDZ protein (IKEPP)

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1823, Issue 10, 2012, Pages 1998-2012

  Reid, Helen M ^a   Turner, Elizebeth C ^a   Mulvaney, Eamon P ^a   Hyland, Paula B ^a   McLean, Caitriona ^a   Kinsella, B Therese ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

GPCR; IKEPP; Interaction; NHERF; Phosphorylation; Prostacyclin receptor

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; INTESTINAL AND KIDNEY ENRICHED PDZ PROTEIN; PDZ PROTEIN; PROSTACYCLIN RECEPTOR; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROTEIN KINASE C; SODIUM PROTON EXCHANGE PROTEIN; UNCLASSIFIED DRUG; LIGAND; PDZD2 PROTEIN, HUMAN; PHOSPHOPROTEIN; PROSTAGLANDIN RECEPTOR; PTGIR PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SODIUM HYDROGEN EXCHANGER REGULATORY FACTOR; SODIUM-HYDROGEN EXCHANGER REGULATORY FACTOR; TUMOR PROTEIN;

ANGIOGENESIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL MIGRATION; COMPLEX FORMATION; CONTROLLED STUDY; GASTROINTESTINAL TRACT; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY PARENCHYMA; LIGAND BINDING; NORMAL HUMAN; PDZ DOMAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM; BIOLOGICAL MODEL; CELL MOTION; CELL STRAIN HEK293; CHEMISTRY; CYTOLOGY; DRUG POTENTIATION; KIDNEY; METABOLISM; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL MOVEMENT; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HEK293 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; KIDNEY; LIGANDS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHOPROTEINS; PROTEIN BINDING; PROTEIN KINASE C; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, PROSTAGLANDIN; SIGNAL TRANSDUCTION; SODIUM-HYDROGEN ANTIPORTER;

EID: 84865289940     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2012.07.015     Document Type: Article

References (62)

1. Jemth P., Gianni S. PDZ domains: folding and binding. Biochemistry 2007, 46:8701-8708.
2. Lee H.J., Zheng J.J. PDZ domains and their binding partners: structure, specificity, and modification. Cell Commun. Signal. 2010, 8:8.
3. Tonikian R., Zhang Y., Sazinsky S.L., Currell B., Yeh J.H., Reva B., Held H.A., Appleton B.A., Evangelista M., Wu Y., Xin X., Chan A.C., Seshagiri S., Lasky L.A., Sander C., Boone C., Bader G.D., Sidhu S.S. A specificity map for the PDZ domain family. PLoS Biol. 2008, 6:e239.
4. Lamprecht G., Seidler U. The emerging role of PDZ adapter proteins for regulation of intestinal ion transport. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291:G766-G777.
5. Thelin W.R., Hodson C.A., Milgram S.L. Beyond the brush border: NHERF4 blazes new NHERF turf. J. Physiol. 2005, 567:13-19.
6. Kocher O., Comella N., Tognazzi K., Brown L.F. Identification and partial characterization of PDZK1: a novel protein containing PDZ interaction domains. Lab. Invest. 1998, 78:117-125.
7. Scott R.O., Thelin W.R., Milgram S.L. A novel PDZ protein regulates the activity of guanylyl cyclase C, the heat-stable enterotoxin receptor. J. Biol. Chem. 2002, 277:22934-22941.
8. Gisler S.M., Stagljar I., Traebert M., Bacic D., Biber J., Murer H. Interaction of the type IIa Na/Pi cotransporter with PDZ proteins. J. Biol. Chem. 2001, 276:9206-9213.
9. 2+ channels TRPV5 and TRPV6 with the intestine- and kidney-enriched PDZ protein NHERF4. Pflugers Arch. 2006, 452:407-417.
10. Lanaspa M.A., Giral H., Breusegem S.Y., Halaihel N., Baile G., Catalan J., Carrodeguas J.A., Barry N.P., Levi M., Sorribas V. Interaction of MAP17 with NHERF3/4 induces translocation of the renal Na/Pi IIa transporter to the trans-Golgi. Am. J. Physiol. Renal Physiol. 2007, 292:F230-F242.
11. Zachos N.C., Hodson C., Kovbasnjuk O., Li X., Thelin W.R., Cha B., Milgram S., Donowitz M. Elevated intracellular calcium stimulates NHE3 activity by an IKEPP (NHERF4) dependent mechanism. Cell. Physiol. Biochem. 2008, 22:693-704.
12. Hegedus T., Sessler T., Scott R., Thelin W., Bakos E., Varadi A., Szabo K., Homolya L., Milgram S.L., Sarkadi B. C-terminal phosphorylation of MRP2 modulates its interaction with PDZ proteins. Biochem. Biophys. Res. Commun. 2003, 302:454-461.
13. Watanabe C., Kato Y., Sugiura T., Kubo Y., Wakayama T., Iseki S., Tsuji A. PDZ adaptor protein PDZK2 stimulates transport activity of organic cation/carnitine transporter OCTN2 by modulating cell surface expression. Drug Metab. Dispos. 2006, 34:1927-1934.
14. Lamprecht G., Gaco V., Turner J.R., Natour D., Gregor M. Regulation of the intestinal anion exchanger DRA. Ann. N. Y. Acad. Sci. 2009, 1165:261-266.
15. Lissner S., Nold L., Hsieh C.J., Turner J.R., Gregor M., Graeve L., Lamprecht G. Activity and PI3-kinase dependent trafficking of the intestinal anion exchanger downregulated in adenoma depend on its PDZ interaction and on lipid rafts. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299:G907-G920.
16. Narumiya S., Sugimoto Y., Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 1999, 79:1193-1226.
17. Woodward D.F., Jones R.L., Narumiya S. International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol. Rev. 2011, 63:471-538.
18. Narumiya S., Furuyashiki T. Fever, inflammation, pain and beyond: prostanoid receptor research during these 25 years. FASEB J. 2011, 25:813-818.
19. Stitham J., Midgett C., Martin K.A., Hwa J. Prostacyclin: an inflammatory paradox. Front. Pharmacol. 2011, 2:24.
20. Tennis M.A., Van Scoyk M., Heasley L.E., Vandervest K., Weiser-Evans M., Freeman S., Keith R.L., Simpson P., Nemenoff R.A., Winn R.A. Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1. Neoplasia 2010, 12:244-253.
21. Tennis M.A., Vanscoyk M., Keith R.L., Winn R.A. The role of prostacyclin in lung cancer. Transl. Res. 2010, 155:57-61.
22. Kawabe J., Ushikubi F., Hasebe N. Prostacyclin in vascular diseases. - Recent insights and future perspectives. Circ. J. 2010, 74:836-843.
23. Kawabe J., Yuhki K., Okada M., Kanno T., Yamauchi A., Tashiro N., Sasaki T., Okumura S., Nakagawa N., Aburakawa Y., Takehara N., Fujino T., Hasebe N., Narumiya S., Ushikubi F. Prostaglandin I2 promotes recruitment of endothelial progenitor cells and limits vascular remodeling. Arterioscler. Thromb. Vasc. Biol. 2010, 30:464-470.
24. Nasrallah R., Clark J., Hebert R.L. Prostaglandins in the kidney: developments since Y2K. Clin. Sci. (Lond.) 2007, 113:297-311.
25. Nasrallah R., Hebert R.L. Prostacyclin signaling in the kidney: implications for health and disease. Am. J. Physiol. Renal Physiol. 2005, 289:F235-F246.
26. Channick R.N., Voswinckel R., Rubin L.J. Inhaled treprostinil: a therapeutic review. Drug Des. Devel. Ther. 2012, 6:19-28.
27. Gomberg-Maitland M., Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur. Respir. J. 2008, 31:891-901.
28. Lawler O.A., Miggin S.M., Kinsella B.T. Protein kinase A-mediated phosphorylation of serine 357 of the mouse prostacyclin receptor regulates its coupling to G(s)-, to G(i)-, and to G(q)-coupled effector signaling. J. Biol. Chem. 2001, 276:33596-33607.
29. Midgett C., Stitham J., Martin K.A., Hwa J. Prostacyclin receptor regulation-from transcription to trafficking. Curr. Mol. Med. 2011, 11:517-528.
30. Miggin S.M., Kinsella B.T. Investigation of the mechanisms of G protein: effector coupling by the human and mouse prostacyclin receptors. Identification of critical species-dependent differences. J. Biol. Chem. 2002, 277:27053-27064.
31. Hayes J.S., Lawler O.A., Walsh M.T., Kinsella B.T. The prostacyclin receptor is isoprenylated. Isoprenylation is required for efficient receptor-effector coupling. J. Biol. Chem. 1999, 274:23707-23718.
32. Miggin S.M., Lawler O.A., Kinsella B.T. Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J. Biol. Chem. 2003, 278:6947-6958.
33. Reid H.M., Mulvaney E.P., Turner E.C., Kinsella B.T. Interaction of the human prostacyclin receptor with Rab11: characterization of a novel Rab11 binding domain within alpha-helix 8 that is regulated by palmitoylation. J. Biol. Chem. 2010, 285:18709-18726.
34. Wikstrom K., Reid H.M., Hill M., English K.A., O'Keeffe M.B., Kimbembe C.C., Kinsella B.T. Recycling of the human prostacyclin receptor is regulated through a direct interaction with Rab11a GTPase. Cell. Signal. 2008, 20:2332-2346.
35. Bockaert J., Fagni L., Dumuis A., Marin P. GPCR interacting proteins. Pharmacol. Ther. 2004, 103:203-221.
36. Bockaert J., Roussignol G., Becamel C., Gavarini S., Joubert L., Dumuis A., Fagni L., Marin P. GPCR-interacting proteins (GIPs): nature and functions. Biochem. Soc. Trans. 2004, 32:851-855.
37. Bockaert J., Marin P., Dumuis A., Fagni L. The 'magic tail' of G protein-coupled receptors: an anchorage for functional protein networks. FEBS Lett. 2003, 546:65-72.
38. Turner E.C., Mulvaney E.P., Reid H.M., Kinsella B.T. Interaction of the human prostacyclin receptor with the PDZ adapter protein PDZK1: role in endothelial cell migration and angiogenesis. Mol. Biol. Cell 2011, 22:2664-2679.
39. Abramovitz M., Boie Y., Nguyen T., Rushmore T.H., Bayne M.A., Metters K.M., Slipetz D.M., Grygorczyk R. Cloning and expression of a cDNA for the human prostanoid FP receptor. J. Biol. Chem. 1994, 269:2632-2636.
40. Bilson H.A., Mitchell D.L., Ashby B. Human prostaglandin EP3 receptor isoforms show different agonist-induced internalization patterns. FEBS Lett. 2004, 572:271-275.
41. Reid H.M., Wikstrom K., Kavanagh D.J., Mulvaney E.P., Kinsella B.T. Interaction of angio-associated migratory cell protein with the TPalpha and TPbeta isoforms of the human thromboxane A(2) receptor. Cell. Signal. 2011, 23:700-717.
42. Doyle D.A., Lee A., Lewis J., Kim E., Sheng M., MacKinnon R. Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ. Cell 1996, 85:1067-1076.
43. Finn R.D., Mistry J., Tate J., Coggill P., Heger A., Pollington J.E., Gavin O.L., Gunasekaran P., Ceric G., Forslund K., Holm L., Sonnhammer E.L., Eddy S.R., Bateman A. The Pfam protein families database. Nucleic Acids Res. 2010, 38:D211-D222.
44. O'Keeffe M.B., Reid H.M., Kinsella B.T. Agonist-dependent internalization and trafficking of the human prostacyclin receptor: a direct role for Rab5a GTPase. Biochim. Biophys. Acta 2008, 1783:1914-1928.
45. Gorman C.M., Gies D., McCray G. Transient production of proteins using an adenovirus transformed cell line. DNA Protein Eng. Tech. 1990, 2:3-10.
46. Suggs J.E., Madden M.C., Friedman M., Edgell C.J. Prostacyclin expression by a continuous human cell line derived from vascular endothelium. Blood 1986, 68:825-829.
47. Turner E.C., Kinsella B.T. Estrogen increases expression of the human prostacyclin receptor within the vasculature through an ERalpha-dependent mechanism. J. Mol. Biol. 2010, 396:473-486.
48. Han J.H., Batey S., Nickson A.A., Teichmann S.A., Clarke J. The folding and evolution of multidomain proteins. Nat. Rev. Mol. Cell Biol. 2007, 8:319-330.
49. Kocher O., Krieger M. Role of the adaptor protein PDZK1 in controlling the HDL receptor SR-BI. Curr. Opin. Lipidol. 2009, 20:236-241.
50. Donnellan P.D., Kimbembe C.C., Reid H.M., Kinsella B.T. Identification of a novel endoplasmic reticulum export motif within the eighth alpha-helical domain (alpha-H8) of the human prostacyclin receptor. Biochim. Biophys. Acta 2011, 1808:1202-1218.
51. Nakamura T., Shibata N., Nishimoto-Shibata T., Feng D., Ikemoto M., Motojima K., Iso O.N., Tsukamoto K., Tsujimoto M., Arai H. Regulation of SR-BI protein levels by phosphorylation of its associated protein, PDZK1. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:13404-13409.
52. Voltz J.W., Brush M., Sikes S., Steplock D., Weinman E.J., Shenolikar S. Phosphorylation of PDZ1 domain attenuates NHERF-1 binding to cellular targets. J. Biol. Chem. 2007, 282:33879-33887.
53. Komhoff M., Lesener B., Nakao K., Seyberth H.W., Nusing R.M. Localization of the prostacyclin receptor in human kidney. Kidney Int. 1998, 54:1899-1908.
54. Nasrallah R., Nusing R.M., Hebert R.L. Localization of IP in rabbit kidney and functional role of the PGI(2)/IP system in cortical collecting duct. Am. J. Physiol. Renal Physiol. 2002, 283:F689-F698.
55. Donowitz M., Cha B., Zachos N.C., Brett C.L., Sharma A., Tse C.M., Li X. NHERF family and NHE3 regulation. J. Physiol. 2005, 567:3-11.
56. Kato Y., Sai Y., Yoshida K., Watanabe C., Hirata T., Tsuji A. PDZK1 directly regulates the function of organic cation/carnitine transporter OCTN2. Mol. Pharmacol. 2005, 67:734-743.
57. Kato Y., Yoshida K., Watanabe C., Sai Y., Tsuji A. Screening of the interaction between xenobiotic transporters and PDZ proteins. Pharm. Res. 2004, 21:1886-1894.
58. Weinman E.J., Steplock D., Zhang Y., Biswas R., Bloch R.J., Shenolikar S. Cooperativity between the phosphorylation of Thr95 and Ser77 of NHERF-1 in the hormonal regulation of renal phosphate transport. J. Biol. Chem. 2010, 285:25134-25138.
59. + exchange regulatory factors. Pharmacol. Rev. 2011, 63:882-900.
60. Fujino T., Nakagawa N., Yuhki K., Hara A., Yamada T., Takayama K., Kuriyama S., Hosoki Y., Takahata O., Taniguchi T., Fukuzawa J., Hasebe N., Kikuchi K., Narumiya S., Ushikubi F. Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I2 receptor IP. J. Clin. Invest. 2004, 114:805-812.
61. Garovic V.D., Textor S.C. Renovascular hypertension and ischemic nephropathy. Circulation 2005, 112:1362-1374.
62. Yuhki K., Kojima F., Kashiwagi H., Kawabe J., Fujino T., Narumiya S., Ushikubi F. Roles of prostanoids in the pathogenesis of cardiovascular diseases: novel insights from knockout mouse studies. Pharmacol. Ther. 2011, 129:195-205.